Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19
0
Authors
Jennifer Hammond
Jennifer Hammond•Heidi Leister‐Tebbe•James Rusnak
Published
February 16, 2022
Abstract
Nirmatrelvir is an orally administered severe acute respiratory syndrome coronavirus 2 main protease (Mpro) inhibitor with potent pan–human-coronavirus activity in vitro.
